The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review

James M. Chang, Heidi E. Kosiorek, Nabil Wasif, Richard J. Gray, Chee Chee H. Stucky, Donald W. Northfelt, Karen Anderson, Ann E. McCullough, Idris Tolgay Ocal, Barbara A. Pockaj

Research output: Contribution to journalArticle

Abstract

Background: The appropriate management of the axilla among women undergoing neoadjuvant therapy is in evolution. Method: A retrospective review of a prospective database of women with breast cancer who underwent neoadjuvant systemic therapy using endocrine/chemotherapy (NE/CT) from 2002 to 2015 was performed. Results: We reviewed 253 women: triple negative breast cancer (30%), ER+HER2- (44%) breast cancer and HER2+ (25%) disease. The mean age was 55 years (SD = 12). 197 patients were analyzed based on their axillary disease. 33 patients (35%) who had clinical N1-3 disease prior to neoadjuvant therapy had no axillary metastases at definitive surgery. There were no significant differences in overall survival or local/regional recurrence between patients who underwent axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB), or SLNB+ALND (p = 0.05061 and p = 0.33). Conclusion: SLNB is a viable technique in patients with breast cancer undergoing NE/CT. Patients with pre-neoadjuvant therapy proven axillary disease may be a candidate for SLNB as opposed to planned ALND with good multidisciplinary review of their response and localization of previously positive lymph nodes.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
DOIs
StateAccepted/In press - 2017
Externally publishedYes

Fingerprint

Sentinel Lymph Node Biopsy
Neoadjuvant Therapy
Lymph Node Excision
Breast Neoplasms
Triple Negative Breast Neoplasms
Axilla
Lymph Nodes
Databases
Neoplasm Metastasis
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Surgery

Cite this

Chang, J. M., Kosiorek, H. E., Wasif, N., Gray, R. J., Stucky, C. C. H., Northfelt, D. W., ... Pockaj, B. A. (Accepted/In press). The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review. American Journal of Surgery. https://doi.org/10.1016/j.amjsurg.2017.08.024

The success of sentinel lymph node biopsy after neoadjuvant therapy : A single institution review. / Chang, James M.; Kosiorek, Heidi E.; Wasif, Nabil; Gray, Richard J.; Stucky, Chee Chee H.; Northfelt, Donald W.; Anderson, Karen; McCullough, Ann E.; Ocal, Idris Tolgay; Pockaj, Barbara A.

In: American Journal of Surgery, 2017.

Research output: Contribution to journalArticle

Chang, JM, Kosiorek, HE, Wasif, N, Gray, RJ, Stucky, CCH, Northfelt, DW, Anderson, K, McCullough, AE, Ocal, IT & Pockaj, BA 2017, 'The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review' American Journal of Surgery. https://doi.org/10.1016/j.amjsurg.2017.08.024
Chang, James M. ; Kosiorek, Heidi E. ; Wasif, Nabil ; Gray, Richard J. ; Stucky, Chee Chee H. ; Northfelt, Donald W. ; Anderson, Karen ; McCullough, Ann E. ; Ocal, Idris Tolgay ; Pockaj, Barbara A. / The success of sentinel lymph node biopsy after neoadjuvant therapy : A single institution review. In: American Journal of Surgery. 2017.
@article{1b5db93e4b6044408c20debcd5011925,
title = "The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review",
abstract = "Background: The appropriate management of the axilla among women undergoing neoadjuvant therapy is in evolution. Method: A retrospective review of a prospective database of women with breast cancer who underwent neoadjuvant systemic therapy using endocrine/chemotherapy (NE/CT) from 2002 to 2015 was performed. Results: We reviewed 253 women: triple negative breast cancer (30{\%}), ER+HER2- (44{\%}) breast cancer and HER2+ (25{\%}) disease. The mean age was 55 years (SD = 12). 197 patients were analyzed based on their axillary disease. 33 patients (35{\%}) who had clinical N1-3 disease prior to neoadjuvant therapy had no axillary metastases at definitive surgery. There were no significant differences in overall survival or local/regional recurrence between patients who underwent axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB), or SLNB+ALND (p = 0.05061 and p = 0.33). Conclusion: SLNB is a viable technique in patients with breast cancer undergoing NE/CT. Patients with pre-neoadjuvant therapy proven axillary disease may be a candidate for SLNB as opposed to planned ALND with good multidisciplinary review of their response and localization of previously positive lymph nodes.",
author = "Chang, {James M.} and Kosiorek, {Heidi E.} and Nabil Wasif and Gray, {Richard J.} and Stucky, {Chee Chee H.} and Northfelt, {Donald W.} and Karen Anderson and McCullough, {Ann E.} and Ocal, {Idris Tolgay} and Pockaj, {Barbara A.}",
year = "2017",
doi = "10.1016/j.amjsurg.2017.08.024",
language = "English (US)",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The success of sentinel lymph node biopsy after neoadjuvant therapy

T2 - A single institution review

AU - Chang, James M.

AU - Kosiorek, Heidi E.

AU - Wasif, Nabil

AU - Gray, Richard J.

AU - Stucky, Chee Chee H.

AU - Northfelt, Donald W.

AU - Anderson, Karen

AU - McCullough, Ann E.

AU - Ocal, Idris Tolgay

AU - Pockaj, Barbara A.

PY - 2017

Y1 - 2017

N2 - Background: The appropriate management of the axilla among women undergoing neoadjuvant therapy is in evolution. Method: A retrospective review of a prospective database of women with breast cancer who underwent neoadjuvant systemic therapy using endocrine/chemotherapy (NE/CT) from 2002 to 2015 was performed. Results: We reviewed 253 women: triple negative breast cancer (30%), ER+HER2- (44%) breast cancer and HER2+ (25%) disease. The mean age was 55 years (SD = 12). 197 patients were analyzed based on their axillary disease. 33 patients (35%) who had clinical N1-3 disease prior to neoadjuvant therapy had no axillary metastases at definitive surgery. There were no significant differences in overall survival or local/regional recurrence between patients who underwent axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB), or SLNB+ALND (p = 0.05061 and p = 0.33). Conclusion: SLNB is a viable technique in patients with breast cancer undergoing NE/CT. Patients with pre-neoadjuvant therapy proven axillary disease may be a candidate for SLNB as opposed to planned ALND with good multidisciplinary review of their response and localization of previously positive lymph nodes.

AB - Background: The appropriate management of the axilla among women undergoing neoadjuvant therapy is in evolution. Method: A retrospective review of a prospective database of women with breast cancer who underwent neoadjuvant systemic therapy using endocrine/chemotherapy (NE/CT) from 2002 to 2015 was performed. Results: We reviewed 253 women: triple negative breast cancer (30%), ER+HER2- (44%) breast cancer and HER2+ (25%) disease. The mean age was 55 years (SD = 12). 197 patients were analyzed based on their axillary disease. 33 patients (35%) who had clinical N1-3 disease prior to neoadjuvant therapy had no axillary metastases at definitive surgery. There were no significant differences in overall survival or local/regional recurrence between patients who underwent axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB), or SLNB+ALND (p = 0.05061 and p = 0.33). Conclusion: SLNB is a viable technique in patients with breast cancer undergoing NE/CT. Patients with pre-neoadjuvant therapy proven axillary disease may be a candidate for SLNB as opposed to planned ALND with good multidisciplinary review of their response and localization of previously positive lymph nodes.

UR - http://www.scopus.com/inward/record.url?scp=85029654663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029654663&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2017.08.024

DO - 10.1016/j.amjsurg.2017.08.024

M3 - Article

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

ER -